The classical viral vaccine approaches using inactivated virus or live-attenuated virus have not been successful for some viruses, such as human immunodeficiency virus or herpes simplex virus. Therefore, new types of vaccines are needed to combat these infections. Replicationdefective mutant viruses are defective for one or more functions that are essential for viral genome replication or synthesis and assembly of viral particles. These viruses are propagated in complementing cell lines expressing the missing gene product; however, in normal cells, they express viral gene products but do not replicate to form progeny virions. As vaccines, these mutant viruses have advantages of both classical types of viral vaccines in being as safe as inactivated virus but expressing viral antigens inside infected cells so that MHC class I and class II presentation can occur efficiently. Replication-defective viruses have served both as vaccines for the virus itself and as a vector for the expression of heterologous antigens. The potential advantages and disadvantages of these vaccines are discussed as well as contrasting them with single-cycle mutant virus vaccines and replicon/amplicon versions of vaccines. Replication-defective viruses have also served as important probes of the host immune response in helping to define the importance of the first round of infected cells in the host immune response, the mechanisms of activation of innate immune response, and the role of the complement pathway in humoral immune responses to viruses. D
Vaccines have been one of the most important innovations in medical science and public health to date because of their ability to reduce morbidity and mortality caused by infectious diseases. The ability to elicit a host immune response that protects against viral disease has been the standard for viral vaccines, and this has been successful for smallpox, poliomyelitis, yellow fever, hepatitis B, influenza, chickenpox, and a number of other viral diseases. Traditionally, viral vaccines have been one of two types, the first being inactivated whole virus particles or viral subunit proteins while the second is live-attenuated virus. Inactivated viral vaccines are essentially inert antigens that induce CD4 + T cell and humoral responses while live-attenuated viruses, which undergo limited replication within the host, elicit CD8 + and CD4 + cellular as well as humoral immune responses without causing disease.
The two classical poliovirus vaccines best illustrate these two different types of vaccines. The inactivated polio vaccine (IPV) developed by Jonas Salk, consists of whole poliovirus rendered noninfectious by formaldehyde treatment. The other polio vaccine, oral polio vaccine (OPV), is a live-attenuated poliovirus developed by Albert Sabin. While both of the polio vaccines are very effective at reducing poliomyelitits, there are advantages and disadvantages to each approach. IPV is very safe because it contains no live virus, but it must be introduced by injection and induces no mucosal immunity. OPV is easily administered to large populations by oral inoculation, but it can revert to a virulent form of poliovirus capable of causing disease. Although both vaccines are effective at preventing disease, only IPV is used now in the U.S. because of its safety.
Other live-attenuated viral vaccines include vaccines for yellow fever, measles, Rubella, chickenpox, and hepatitis A. Other killed virus vaccines include influenza and rabies, while the hepatitis B vaccine is a subunit vaccine.
However, for some viruses such as human immunodeficiency virus (HIV) or herpes simplex virus (HSV), these classical approaches to viral vaccines have not been successful. Thus, new vaccine approaches need to be developed. For AIDS vaccines, live-attenuated simian immunodeficiency virus (SIV) has been the only successful approach for immunization against SIV (Daniel et al., 1992) , but there are concerns about whether a live-attenuated HIV can ever be made safe enough for widespread immunization of healthy individuals. Meanwhile, subunit vaccines do not induce the CD8 + T cell responses needed for protection against HIV, so alternative vaccine approaches are needed. Similarly, it has not been possible to attenuate herpes simplex virus so that it is safe but still immunogenic (Koelle and Corey, 2003) .
Viruses that persist in the host raise another level of complexity in terms of vaccine design and implementation.
For these viruses, immunization needs to reduce infection to as low a level as possible, not just prevent primary disease, because viral infection of the appropriate cells can lead to establishment of a persistent infection. As with HIV infection of CD4 + T cells, this could ultimately lead to disease due to viral persistence and reactivation and disease.
Replication-defective mutant viruses
Replication-defective viral mutant strains provide a new form of viral vaccine that combines some of the advantages of each of the two classic vaccine forms. Replication-defective mutant viruses are specifically defective for viral functions that are essential for viral genome replication and assembly of progeny virus particles. They are propagated in complementing cell lines that express the missing viral gene product(s), allowing viral replication (Fig. 1, top panel) . In contrast, in normal cells, one or more steps in viral replication are blocked, resulting in viral gene expression within the infected cell but no progeny virus production. The tight block in replication for these mutant viruses makes their high level of safety one of the main advantages for the use of replication-defective mutant viruses as vaccines. Probably the first use of replicationdefective viruses as a vaccine for that microbe was the use of replication-defective HSV-1 strains to protect mice against HSV-1 infection (Nguyen et al., 1992) . At the time of that publication, it was surprising that a replication-defective mutant virus could induce protective immunity because it was generally thought that viral vaccines had to be delivered as either a replicating virus or a large amount of inactivated viral antigen to induce a protective immune response (Murphy and Chanock, 1990) . In the study of Nguyen et al. (1992) , both immediate-early and early gene mutant viruses protected mice against HSV-1 infection. These viruses are absolutely defective for viral replication, yet the protective immunity is durable for at least 7 months in mice (Morrison and Knipe, 1996) . Surprisingly, the magnitude and durability of the immune responses are equal for the replication-defective mutant virus and its replication-competent parental virus, arguing that the bulk of the immune responses are generated against viral gene products expressed in the first round of infected cells (Morrison and Knipe, 1996) . This raised the importance of the first round of infected cells, presumably including antigen-presenting cells, in eliciting antiviral immune responses.
Replication-defective mutant viruses provide important probes in the study of immune response mechanisms as, due to their replication-defect, their infection is largely restricted to the site of inoculation. Replication-defective HSV mutant strains have provided a model system for the study of the role of complement in immune responses to viral infection at a peripheral tissue site following intradermal inoculation (Da Costa et al., 1999a , 1999b . In these studies, the complement pathway has been shown to be essential for humoral responses to viral infection (Da Costa et al., 1999a , 1999b , and these complement components are provided by myeloid cells either in the dermis or in draining lymph nodes (Verschoor et al., 2001 (Verschoor et al., , 2003 .
Replication-defective viruses have also been used as vaccine vectors to express heterologous antigens to induce immune responses against other microbes. Probably the first use of this vector approach was a fowlpox recombinant virus expressing rabies glycoprotein that protected mice, cats, and dogs against lethal infection by rabies virus (Taylor et al., 1988) . A number of applications of replication-defective viruses as vaccines and vaccine vectors have been reported, and we will discuss the major advances with these recombinant viruses in this review.
Single-cycle mutant viruses
A somewhat similar but technically different form of viral vaccine is the single-cycle mutant virus. These mutant viruses are defective in a virion protein that functions after viral assembly. The viruses are propagated in complementing cells that express the missing gene product (Fig. 1, bottom panel) . In normal cells, the replication cycle occurs normally and progeny virions are produced. However, these virions are noninfectious so the infection does not spread to a second round of cells. The released, noninfectious virions may provide inert antigen that can spread beyond the infected cell; nevertheless, the block in spread may not be complete for all of these viruses (Loudon et al., 2001) , as discussed below. Thus, there are potential advantages and disadvantages to the single-cycle mutant viruses.
Amplicon or replicon vaccines
Amplicon or replicon genomes contain the minimal cisacting signals for viral genomic replication, an origin of replication and packaging signals. The viral proteins needed for genomic replication and virion formation are supplied by a helper virus or a ''packaging'' cell line. These defective viruses have been used mostly as vaccine vectors with the transgene inserted into the minimal viral genome needed for replication and packaging into virions.
Replication-defective viruses as vaccines

Herpes simplex virus
Herpes simplex virus 1 and 2 are common human pathogens that cause mucosal infections and spread to and establish latent infections in sensory neurons. They later can reactivate to cause recurrent disease. HSV infections occur throughout life and present as a variety of clinical syndromes. These include neonatal HSV infection, HSV orolabialis, herpetic whitlow, HSV infection of eczematous skin, HSV keratitis, HSV encephalitis, and HSV genitalis. HSV can also cause severe disease in the immunocompromised such as those with HIV/ AIDS. The large economic and disease burden caused by HSV disease and the likely contributory role of genital herpes infection in the HIV/AIDS pandemic drive the efforts to find an effective HSV vaccine (Jones and Knipe, 2003) . HSV glycoprotein subunit vaccines have either provided no clinical protection (Corey et al., 1999) or limited protection in HSVseronegative women only (Stanberry et al., 2002) , likely because no HSV-specific CD8 + T cell responses were induced. A live-attenuated HSV recombinant showed limited immunogenicity (reviewed in Koelle and Corey, 2003) ; thus, new types of herpes vaccines are needed.
The use of replication-defective HSV as a vaccine
HSV-1 replication-defective mutant viruses were first used to induce protection in mice against virulent HSV-1 infection (Morrison and Knipe, 1994; Nguyen et al., 1994 ). An HSV-2 replication-defective mutant was then used to induce protection in guinea pigs against HSV-2 infection (Da Costa et al., 1997) . These mutants can infect normal cells and express immediateearly, early, and some of the late proteins, but are blocked for DNA synthesis and therefore do not complete the replication cycle (Fig. 1, top panel) .
For increased safety in a newer vaccine virus strain, two HSV-2 genes essential for viral DNA synthesis and viral replication, U L 5 and U L 29, were deleted from HSV-2 to generate the dl5-29 vaccine candidate virus (Da Costa et al., 1999a , 1999b Da Costa et al., 2000) . U L 5 encodes one of the three known components of the viral helicase -primase complex, while U L 29 encodes ICP8, a single-stranded DNA-binding protein. In a murine infection model, dl5-29 protects mice against a highly lethal challenge with wild-type HSV-2 (Da Costa et al., 1999a , 1999b . Recently, dl5-29 was tested side-by-side with a recombinant HSV-2 glycoprotein D (gD2) subunit vaccine in Freunds' adjuvant. Surprisingly, dl5-29 elicits significantly higher neutralizing antibody titers and increased levels of HSV-2-specific CD8 + T cells than the gD2 vaccine (Hoshino et al., 2005) . This translated into similar protection as a prophylactic vaccine and stronger efficacy as a therapeutic vaccine in the guinea pig animal model system (Hoshino et al., 2005) .
The HSV-2 dl5-29 virus also has a defect in establishing and/or maintaining a latent infection (Da Costa et al., 1999a , 1999b . When inoculated at peripheral sites, very little viral DNA reaches the ganglion and this viral DNA is rapidly lost from the ganglia (Da Costa et al., 1999a , 1999b . The lack of latent infection by this viral strain is an important additional safety feature of dl5-29. The dl5-29 vaccine is being prepared currently for clinical trials.
Single-cycle HSV mutants as a vaccine HSV mutants lacking the glycoprotein H (gH) gene are grown on complementing cells containing the HSV gH gene (Fig. 1, bottom panel) . The mutant virus can infect normal cells and undergo a single cycle of replication (Forrester et al., 1992) ; thus, these viruses are replication-competent as described by Farrell et al. (1994) . However, the viruses produced by this infection are unable to infect the next round of cells. HSV-1 gH mutants can protect mice against HSV-1 infection in the ear (Farrell et al., 1994) and guinea pigs against HSV-2 genital infection . Although the HSV-1 gH mutant virus is considered to be limited to a single cycle, latent viral infections are detected after in vivo inoculation of the virus, as evidenced by in situ hybridization detection of the latency-associated transcript (LAT) expression (Loudon et al., 2001) . Because establishment of latent infection involves spread from cell to cell, this mutant may be leaky for replication in vivo. A HSV-2 gH mutant virus was able to protect guinea pigs when used for immunization either prophylactically or therapeutically (Boursnell et al., 1997) . Although this virus elicited protective and therapeutic immunity in preclinical animal studies, it failed to show any therapeutic benefits in a Phase II trial.
Replication-defective poxviruses as smallpox vaccines
Poxviruses are large, enveloped, double-stranded DNA viruses containing genomes of 130-230 kbp, the prototype virus being variola major, the causative agent of smallpox. Efforts at immunization against smallpox have a long and rich history, and in fact, vaccination in its modern sense began in 1796 when Edward Jenner proved that deliberate inoculation with cowpox could prevent smallpox. Cowpox virus was used as a vaccine for smallpox, but over many years of propagation, the stocks became contaminated with another poxvirus that was named vaccinia virus. The world-wide eradication of smallpox was completed in 1980 after a vaccination program using liveattenuated vaccinia virus as the vaccine. Smallpox vaccination was stopped in the U.S. in 1972, but concerns about the use of smallpox virus as a potential agent of bioterrorism and the emergence of monkeypox in the U.S. (Sejvar et al., 2004) have regenerated interest in smallpox vaccines. Although vaccinia virus was effective as a smallpox vaccine, there are concerns about its safety, because the vaccine strains can cause disseminated infection in immunocompromised individuals and individuals with atopic dermatis. In addition, rare cardiac complications can arise. Thus, new vaccines are being studied.
One of the new smallpox candidates being tested is the Modified Vaccine Ankara or MVA strain of vaccinia virus, which was derived by passage in chicken cells (Mayr et al., 1975) . During passage in chicken cells, MVA lost about 15% of the vaccinia virus genome, including genes needed for replication in human cells, pathogenicity, and blocking the host immune response. MVA is effectively replication-defective in primary human fibroblasts (C. Lee, personal communication). MVA induces protection against monkeypox in nonhuman primates and protects immunocompetent and immunodeficient mice against virulent vaccinia virus infection . Thus, MVA appears to be a safe and efficacious vaccine candidate against both monkeypox and smallpox infection.
A replication-defective mutant vaccinia virus, dVV-L, has also been derived from the highly attenuated Elstree/Lister strain of vaccinia by deletion of the essential gene encoding the uracil-DNA-glycosylase enzyme. This deletion renders the virus completely replication-defective (Holzer and Falkner, 1997) . Immunization studies have shown that responses to dVV-L are comparable to those of MVA and Wyeth strains of vaccinia (Coulibaly et al., 2005) . This mutant may have some growth and production advantages over MVA or other strains that grow in primary cells.
Other replication-defective mutants as vaccines
Other replication-defective mutants are also being considered as vaccines. For example, an influenza NS2-knockout virus provided protective immunity in mice against a pathogenic influenza strain (Watanabe et al., 2002) . In addition, immunization of rhesus macaques with genetically engineered, single-cycle simian immunodeficiency virus mutant virus reduced viral load after challenge with pathogenic SIVmac239 (Evans et al., 2005) .
Replication-defective viruses as vaccine vectors
Poxvirus
The use of fowlpox virus recombinants in mammals was the first use of a replication-defective vaccine vector (Taylor et al., 1988) . Poxviruses are strong candidates for vaccine vectors because they grow to high titers, are very stable when lyophilized, and are capable of accepting large transgene sequences. The replication-competent strains of poxviruses used as smallpox vaccines have been used to create vaccine vectors against homologous pathogens but concerns about their safety remain.
The avipoxvirus vectors have a good safety profile because their replication is restricted to avian species, and they are incapable of replication in mammalian cells. In addition, there is little no natural immunity against the avipoxviruses found within humans. These properties make avipoxviruses attractive replication-defective vaccine vectors.
Two avipoxviruses that have been employed as vaccine vectors are fowlpox and canarypox. Canarypox has been shown to be more efficacious within mammalian cells than fowlpox and has been used to develop vaccines against many diseases including HIV (Abimiku et al., 1995; Girard et al., 1995) , rabies (Taylor et al., 1991) , measles (Taylor et al., 1992) , and malaria (Rogers et al., 2001 ). Both of these avipoxviruses have even been studied in human clinical trials, but CD8 + T cell responses have been disappointing (Konishi et al., 1998; Marshall et al., 1999) .
Modified vaccina virus Ankara (MVA) has been used not only as a vaccine but also as an effective vaccine vector (Sutter and Moss, 1992) . Effective immune responses have been elicited using MVA against a variety of pathogens, including HIV (Amara et al., 2001; Hirsch et al., 1996) , influenza (Sutter et al., 1994) , measles (Stittelaar et al., 2000) , dengue (Men et al., 2000) , and malaria (Schneider et al., 1998) . The ability of MVA vectors to elicit protective immunity combined with its safety has brought various MVA vaccine vectors into clinical trials (reviewed in Drexler et al., 2004) .
Adenovirus
Replication-incompetent recombinant adenoviruses are perhaps the most widely studied and used replication-defective vaccine vectors. Adenoviruses are nonenveloped, doublestranded DNA viruses with genomes of approximately 36 kbp. First-generation adenovirus vectors were rendered replication-defective by deletion of the E1 region of the genome, which is required for viral replication and gene expression, and insertion of the transgene expression cassette. Because the E1 functions are not absolutely essential for viral replication, these vectors were capable of some low-level replication. Further modifications have been made to abrogate their ability to replicate, including mutations within the E2A region and/or deletions of E2a, E3, and/or E4 regions (reviewed in Lai et al., 2002; Tatsis and Ertl, 2004) .
Replication-defective adenovirus vectors are extremely safe, stable, and easily produced in high titers, can be lyophilized and administered through various routes, and have a broad host cell range. They express transgenes to high levels, activate the innate immune system, and stimulate dendritic cell maturation (Morelli et al., 2000; Rea et al., 1999; Tan et al., 2005) leading to elicitation of strong immune responses. Recently, helperdependent adenoviral vectors (HdAd) have been examined for their ability to elicit an immune response. These vectors carry DNA that only contains the inverted terminal repeats and the packing signal from adenovirus, each necessary for vector propagation. This allows for an increased cloning capacity of up to 37 kb (Mitani et al., 1995) . The major disadvantages to adenovirus vectors are that, with the exception of HdAd vectors, they can only tolerate small heterologous sequences, up to 9 kb, and preexisting immunity to adenoviruses can dampen the effectiveness of the vectors (Shiver and Emini, 2004; Xiang et al., 2002) . To overcome preexisting immunity, numerous human serotypes have been used, as well as nonhuman adenoviruses (Shiver and Emini, 2004; Tatsis and Ertl, 2004) .
Adenovirus recombinants have been used to protect animals against pathogenic challenge with various pathogens such as SHIV (Shiver et al., 2002) , Ebola (Sullivan et al., 2000) , swine influenza virus measles (Schindler et al., 1994) , malaria (Rodrigues et al., 1997) , tuberculosis (BrunaRomero et al., 2001; Tsuji et al., 1998; Wang et al., 2004) , and anthrax lethal toxin (Tan et al., 2003) .
Alphavirus
There is growing use of alphavirus vaccine vectors because of their broad host cell range, their tropism for dendritic and monocytic cells (MacDonald and Johnston, 2000; Ryan et al., 2000) , their ability to stimulate innate immune receptors (Saiku et al., 2003) , their high levels of transgene expression, and lack of preexisting immunity within the human population. Alphaviruses are members of the Togaviridae family. They are enveloped viruses with single-stranded, positive-strand RNA genomes. The 5V end of the genome encodes the nonstructural genes, while the 3V end encodes the structural genes. The nonstructural genes are translated from the genomic RNA after its release into the cell cytoplasm. These nonstructural proteins form a replication complex that drives the production of the negative-stranded anti-genomic RNA and also transcribes the full-length positive stranded genomic RNA and a shorter subgenomic RNA. The subgenomic RNA encodes the structural genes. This arrangement allows for rapid multiplication of subgenomic mRNA in that as the full genomic RNA is replicated there are more templates for transcription through the subgenomic promoter, leading to exponential amplification of the subgenomic RNA. Alphaviral replicons are created by the replacement of the structural genes with heterologous genes, abrogating the virus' ability to replicate due to the loss of its structural genes while allowing for extremely high expression of the transgene (reviewed in Rayner et al., 2002; Schlesinger and Dubensky, 1999) .
Alphaviral replicon vectors are being developed using Sindbis virus, Semliki Forest virus, and Venezuelan equine encephalitis virus. These vectors have elicited protective immunity against a wide variety of pathogens including SHIV (Berglund et al., 1997) , influenza (Pushko et al., 1997) , Marburg virus (Hevey et al., 1998) , Ebola (Pushko et al., 2000) , measles (Pan et al., 2005) , and malaria (Tsuji et al., 1998) .
Herpes simplex virus
HSV makes an attractive vaccine vector in that it is highly infectious for an extremely broad host cell range, activates the innate immune system through Toll-like receptors (Kurt-Jones et al., 2004; Lund et al., 2003) , can accommodate large insertions of heterologous DNA at numerous loci within its genome, can infect and express antigen within nondividing cells, and produces high titer stocks. HSV induces a durable immune response, and even replication-defective mutants induce long-lived immunity (Morrison and Knipe, 1996) .
Vaccination of rhesus macaques with replication-defective HSV-1 recombinant expressing SIV antigens showed partial protection against mucosal challenge with the pathogenic SIVmac239 virus in the vaccinated monkeys (Murphy et al., 2000) . In addition, a mutant HSV-1 deleted for the ICP4, ICP22, and ICP27 genes and expressing ovalbumin as a model antigen elicited protection against a lethal challenge with a recombinant Listeria monocytogenes expressing OVA (Lauterbach et al., 2004) .
Further improvements in HSV vaccine vectors are recombinants deleted for four immediate-early genes, ICP4, ICP22, ICP27, and ICP47 (Samaniego et al., 1998; Watanabe, D., Brockman, M.A., Mathews, L., Ndung'u, T., Pavlakis, G., Desrosiers, R., DeLuca, N.A., Knipe, D.M., manuscript in preparation) . Recombinants expressing SIV genes products are immunogenic in rhesus macaques and induce partial protection against intravenous challenge with the highly pathogenic SIVmac239 virus (Kaur, A., Sanford, H., Gerry, D., Watanabe, D., Lifson, J., Pavlakis, G., Knipe, D., Desrosiers, R., manuscript in preparation). Protection against intravenous challenge with this virus had previously been achieved only with live-attenuated SIV; therefore, this vector shows great promise.
Due to the high prevalence of HSV infection within the human population, a possible drawback to the use of HSV based vectors is the presence of preexisting anti-HSV immunity and its potential ability to reduce vector efficacy. The effect of preexisting immunity on HSV vectors remains controversial, with some studies showing strong immune responses in the face of anti-HSV immunity (Brockman and Knipe, 2002; Hocknell et al., 2002) while another study showed a reduction in immune responses to a transgene (Lauterbach et al., 2005) .
HSV-derived amplicon systems have been produced to use as vaccine vectors. In one system, cells are cotransfected with a BAC containing a packaging signal deleted HSV genome, needed to create the HSV delivery vehicle, and a HSV amplicon plasmid, containing the HSV packaging signal and the transgene of interest (Suter et al., 1999) . The resulting amplicon virus is devoid of any HSV DNA with the exception of the packaging signal. The amplicon plasmid is packaged as genome length (152 kb) concatamers, allowing for high levels of transgene expression in transduced cells (Geller and Breakefield, 1988; Spaete and Frenkel, 1982) . HSV amplicons expressing HIV gp120 are highly immunogenic in mice (Hocknell et al., 2002) and show some protection of hu/SCID mice challenged with HIV (Gorantla et al., 2005) . Thus far, titers of these amplicon vectors seem to be limiting for vaccine production.
Other vaccine vectors
Replication-defective vaccine vectors have been produced with many other viruses, including adeno-associated virus (AAV), poliovirus, and Sendai virus.
AAV is a small, nonenveloped helper-dependent parvovirus, with a genome of 4.7 kbp. While AAV is commonly found in humans, it has no known pathology. AAV replication requires coinfection with a helper virus, such as an adenovirus or herpes virus. Recombinant AAV (rAAV) is produced by removal of endogenous viral genes and insertion of a transgene expression cassette between the inverted terminal repeats of AAV. This recombinant vector DNA is transfected into a cell expressing the AAV Rep and Cap proteins and then helper functions are provided to that cell, often by superinfection with adenovirus. rAAV expressing SIV genes has recently been shown to elicit an immune response that significantly limited the replication of SIV after a virulent challenge (Johnson et al., 2005) .
There is a long history of safety involving the use of a live poliovirus in humans through vaccination programs with OPV. This relative safety is further improved by rendering the virus replication-defective. Poliovirus replicons are produced by insertion of the transgene into the virion coat protein VP1 capsid gene, transfection of replicon RNA into cells, and infection of those cells with a helper virus. Replicon RNA is packaged into the poliovirus particle, rendering an infectious virus (Moldoveanu et al., 1995) . Pig-tailed macaques immunized with poliovirus replicons expressing HIV and SIV proteins and HIV and SIV recombinant proteins elicited protective immunity against a lethal pathogenic SHIV challenge. This protection was above that of recombinant protein alone (Fultz et al., 2003) . Poliovirus replicons have also elicited protective responses against tetanus toxin in the face of preexisting immunity (Porter et al., 1997) and have shown prophylactic and therapeutic efficacy against Helicobacter pylori (Smythies et al., 2005) .
Sendai virus is an enveloped, negative-strand RNA virus from the Paramyxoviridae family with a genome of approximately 15 kb. A replication-defective Sendai virus has been produced by deleting the gene encoding the fusion protein (F) required for viral entry (Li et al., 2000) . A DNA prime and SeV boost this immunization protocol-elicited protection in cynomolgous macaques against a pathogenic SHIV challenge (Takeda et al., 2003) .
Perspectives
Replication-defective viruses provide unique forms of viral vaccines that combine the safety of a killed virus vaccine and the immunogenicity of a live virus vaccine by expressing gene products within cells so the antigens can be presented efficiently by both MHC class I and class II pathways. Replicationdefective viruses can also activate Toll-like receptors and other innate immune response pathways, thereby serving as their own adjuvants. In addition, replication-defective viruses can be used as tools to investigate the workings of the immune system. Studies with these vectors have defined mechanisms of innate response stimulation, the role of primary infected cells in the immune response, and the role of complement in the host immune response. However, there is still much to learn about the mechanisms of host responses and the interaction between viruses and the host. Future research on viral vaccines and vaccine vectors should be directed at gaining a basic understanding of the connection between host innate and adaptive immune responses, how specific viruses activate or inactivate innate host responses, and how we can minimize the ability of the virus or viral vector to block the host response while maximizing its ability to stimulate a protective immune response. This may include targeting to specific immune cells such as dendritic cells, stimulation of innate immune receptors like Toll-like receptors, the induction of type I interferons and cytokines, and elimination of virus-mediated evasion of these host responses.
